Assuming compared is required, the following results were found.

  • Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.

    to treatment start within 2 years of onset (N = 140) or later (N = 151). Annualised relapse rate in each study group was compared using a negative binomial regression; and Cox proportional hazard model was used to estimate hazard ratios (HR) of time to...

    https://mschristian.org/index.php/blog/long-term-effect-of-delayed-treatment-on-disability-in-patients-with-paediatric-onset-multiple-sclerosis-a-prospective-danish-cohort-study
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    presence of Gd-enhancing T1 lesions at baseline. The baseline characteristics were similar except for signs of activity compared to the overall population. Results from EXPAND in the overall population showed that Mayzent significantly reduced the risk...

    https://mschristian.org/index.php/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Aubagio (teriflunomide)

    Aubagio comes as a tablet that you swallow. The drug is available in two strengths: 7 mg and 14 mg. Aubagio was compared to a placebo (no treatment) in four clinical trials. People who took Aubagio had: Table of contents FDA warnings This drug has boxed...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • Aubagio (teriflunomide)

    Aubagio comes as a tablet that you swallow. The drug is available in two strengths: 7 mg and 14 mg. Aubagio was compared to a placebo (no treatment) in four clinical trials. People who took Aubagio had: fewer relapses (flare-ups) slower progression of...

    https://mschristian.org/index.php/articles/2-uncategorised/8433-aubagio-teriflunomide
  • New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis

    Ocrevus treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) patients compared with patients who switched from interferon beta-1a two years later – – Separate analysis showed Ocrevus slowed thalamic...

    https://mschristian.org/index.php/blog/new-6-year-data-for-genentech-s-ocrevus-ocrelizumab-show-earlier-treatment-initiation-nearly-halves-risk-of-needing-walking-aid-in-relapsing-multiple-sclerosis
  • Tecfidera (dimethyl fumarate)

    Both Tecfidera and Aubagio are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, in one analysis, they were compared indirectly and were found to have similar benefits. Costs...

    https://mschristian.org/index.php/articles/2-uncategorised/8434-tecfidera-dimethyl-fumarate
  • Cannabis-based drug in combination with other anti-spasticity

    Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs. Chemical compounds derived from the cannabis sativa plant given as an add-on treatment may...

    https://mschristian.org/index.php/blog/cannabis-based-drug-in-combination-with-other-anti-spasticity
  • Tecfidera (dimethyl fumarate)

    Both Tecfidera and Aubagio are effective for treating MS. The effectiveness of these drugs hasn't been directly compared in clinical studies. However, in one analysis, they were compared indirectly and were found to have similar benefits. Costs...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • Cannabis-based drug in combination with other anti-spasticity

    Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs. Chemical compounds derived from the cannabis sativa plant given as an add-on treatment may...

    https://mschristian.org/index.php/articles/2-uncategorised/4679-cannabis-based-drug-in-combination-with-other-anti-spasticity
  • Disabled workers paid 12% less, 'damning' UK official figures show - The Guardian

    and lack of understanding of disability hold people back The median pay for disabled employees in 2018 was £10.63 an hour, compared with £12.11 an hour for their non-disabled counterparts. Photograph: GrapeImages/Getty Images Disabled people continue to...

    https://mschristian.org/index.php/blog/disabled-workers-paid-12-less-damning-uk-official-figures-show-the-guardian
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    into 2021 The Company reported a net loss of $71.9 million, or $1.31 per share, for the third quarter of 2019 as compared to $58.4 million, or $1.29 per share, for the same period in 2018 Total operating expenses include non-cash stock-based...

    https://mschristian.org/index.php/blog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Siponimod Delays Time to Wheelchair in Secondary Progressive MS - Neurology Times

    and colleagues, only 19.8% of siponimod-treated patients with a baseline EDSS of 6.5 progressed to a score of ≥7, compared to 26.1% of placebo patients, equating to a risk reduction of 36% (hazard ratio [HR], 0.64; 95% CI, 0.41–1.0; P = .0483). In the...

    https://mschristian.org/index.php/blog/siponimod-delays-time-to-wheelchair-in-secondary-progressive-ms-neurology-times
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    presence of Gd-enhancing T1 lesions at baseline. The baseline characteristics were similar except for signs of activity compared to the overall population. Results from EXPAND in the overall population showed that Mayzent significantly reduced the risk...

    https://mschristian.org/index.php/articles/2-uncategorised/9270-novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    into 2021 The Company reported a net loss of $71.9 million, or $1.31 per share, for the third quarter of 2019 as compared to $58.4 million, or $1.29 per share, for the same period in 2018 Total operating expenses include non-cash stock-based...

    https://mschristian.org/index.php/articles/2-uncategorised/9192-atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

    had a change on the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain subscale of -2.85 at week 24 compared with -2.24 for those receiving placebo, for a mean difference of -0.62 (P=0.0006), according to Francis Berenbaum, MD, PhD,...

    https://mschristian.org/index.php/blog/tanezumab-a-win-as-last-ditch-osteoarthritis-tx
  • Mindfulness training may be helpful in more than one way for people with MS

    and improving processing speed. People with MS who underwent the four-week mindfulness training not only improved more compared to those who did nothing - they also improved compared to those who tried another treatment, called adaptive cognitive...

    https://mschristian.org/index.php/mindfulness-training-may-be-helpful-in-more-than-one-way-for-people-with-ms
  • Antiviral cocktail may help treat mild COVID-19 patients

    is when the virus is detectable and potentially transmissible. The drug trial The trial, which involved 127 patients, compared the effect of the triple-drug combination, including the anti-HIV therapy lopinavir-ritonavir, the multiple sclerosis...

    https://mschristian.org/index.php/antiviral-cocktail-may-help-treat-mild-covid-19-patients
  • Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.

    to treatment start within 2 years of onset (N = 140) or later (N = 151). Annualised relapse rate in each study group was compared using a negative binomial regression; and Cox proportional hazard model was used to estimate hazard ratios (HR) of time to...

    https://mschristian.org/index.php/articles/2-uncategorised/9972-long-term-effect-of-delayed-treatment-on-disability-in-patients-with-paediatric-onset-multiple-sclerosis-a-prospective-danish-cohort-study
  • Demyelinating Risks With Anti-TNF Vary in Rheumatic Diseases - MedPage Today

    psoriatic arthritis (PsA) who were exposed to TNF inhibitors, there was a 50% greater risk for any neuroinflammatory event compared with unexposed patients (HR 1.50, 95% CI 1.07-2.11), according to Tine Iskov Kopp, PhD, of the department of neurology at...

    https://mschristian.org/index.php/blog/demyelinating-risks-with-anti-tnf-vary-in-rheumatic-diseases-medpage-today
  • Disabled workers paid 12% less, 'damning' UK official figures show - The Guardian

    and lack of understanding of disability hold people back The median pay for disabled employees in 2018 was £10.63 an hour, compared with £12.11 an hour for their non-disabled counterparts. Photograph: GrapeImages/Getty Images Disabled people continue to...

    https://mschristian.org/index.php/articles/2-uncategorised/9427-disabled-workers-paid-12-less-damning-uk-official-figures-show-the-guardian

Results 1 - 20 of 169